Connexin Therapeutics Ltd.

Connexin Therapeutics Ltd. develops novel small molecule drugs targeting connexins, specifically Cx36 and Cx45, to protect retinal neurons and preserve vision in glaucoma and other eye diseases. Their lead program focuses on Cx36 inhibition for glaucoma neuroprotection, with demonstrated efficacy in zebrafish, mouse, and primate models. The company has an exclusive license from the Research Foundation for SUNY based on technology developed by Dr. Stewart Bloomfield’s lab at SUNY College of Optometry. As of the most recent updates, they are advancing through preclinical development with plans to out-license or partner after further validation.